Neurological complications of coronary heart disease and their management

Waqar, Aneeq; López, John J.

doi:10.1016/b978-0-12-819814-8.00024-x

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the current treatment for CHD patients mainly focuses on improving the ischemia (such as nitroglycerin and percutaneous coronary intervention), anti‐thrombogenesis (such as aspirin), lipid‐lowering therapy (such as statins), etc 6,7 . Unfortunately, even though these intensive therapies are applied to CHD patients, a non‐neglectable proportion of patients still might occur dismal outcomes such as myocardial infarction, heart failure, and even death 8–11 . Therefore, it is essential to find biomarkers that might reflect the disease risk and progression of CHD, which could help the cardiologist to stratify the patients and further improve the prognosis of CHD patients.…”

Section: Introductionmentioning

confidence: 99%

“…6,7 Unfortunately, even though these intensive therapies are applied to CHD patients, a non-neglectable proportion of patients still might occur dismal outcomes such as myocardial infarction, heart failure, and even death. [8][9][10][11] Therefore, it is essential to find biomarkers that might reflect the disease risk and progression of CHD, which could help the cardiologist to stratify the patients and further improve the prognosis of CHD patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical value of long non‐coding RNA KCNQ1OT1 in estimating the stenosis, lipid level, inflammation status, and prognostication in coronary heart disease patients

Zhu

Feng

Fan

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Objective Long non‐coding RNA KQT‐like subfamily, member 1 opposite strand/antisense transcript 1 (KCNQ1OT1) could regulate lipid metabolism, vascular smooth muscle cell function, inflammation, and atherosclerosis. This study aimed to evaluate whether lncRNA KCNQ1OT1 could serve as a biomarker for reflecting coronary heart disease (CHD) patients' disease situation and prognosis. Methods LncRNA KCNQ1OT1 expression was determined in peripheral blood mononuclear cells from 267 CHD patients, 50 disease controls (DCs) (unexplained chest pain), and 50 healthy controls (HCs) by the RT‐qPCR method. TNF‐α, IL‐17A, VCAM‐1, and ICAM‐1 were determined by the ELISA procedure in serum from CHD patients only. The mean (95% confidential interval) follow‐up duration was 16.0 (15.3–16.8) months. Results LncRNA KCNQ1OT1 was highest in CHD patients, followed by DCs, and lowest in HCs (p < 0.001). LncRNA KCNQ1OT1 could distinguish the CHD patients from DCs (area under the curve [AUC]: 0.757) and from the HCs (AUC: 0.880). LncRNA KCNQ1OT1 was positively associated with triglyceride (p = 0.026), low‐density lipoprotein cholesterol (p = 0.023), cardiac troponin I (p = 0.023), and C‐reactive protein (p = 0.001). Besides, lncRNA KCNQ1OT1 was also positively linked with the Gensini score (p = 0.008). Furthermore, lncRNA KCNQ1OT1 was positively related to the TNF‐α (p < 0.001), IL‐17A (p = 0.008), and VCAM‐1 (p = 0.003). LncRNA KCNQ1OT1 was elevated in CHD patients with MACE compared to those without MACE (p = 0.006); moreover, lncRNA KCNQ1OT1 high was associated with shorter MACE‐free survival (p = 0.018). Conclusion Circulating lncRNA KCNQ1OT1 expression not only reflects the stenosis degree, blood lipid level, and inflammation status but also predicts the MACE risk, while a large‐scale study is needed for verification.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical value of long non‐coding RNA KCNQ1OT1 in estimating the stenosis, lipid level, inflammation status, and prognostication in coronary heart disease patients

Zhu

Feng

Fan

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

Improvements in functionality and quality of life after aquatic therapy in stroke survivors

Auza-Santivañez,

Condori-Villca,

Oberson Santander

et al. 2023

AG Salud

View full text Add to dashboard Cite

The paper discusses the vital importance of water in living beings and its application in hydrotherapy for the rehabilitation of stroke patients. Water is highlighted as an essential molecule for life, support of metabolic reactions, transport of substances, and important reactant in metabolic processes. Hydrotherapy, significantly developed by Kneipp, uses the mechanical and thermal properties of water for therapeutic purposes, taking advantage of its capacity as a rehabilitative medium in patients with various conditions, including those affected by stroke. The physiology of stroke is described, being a major cause of mortality and disability, and how water exercises can improve the functional capacity and quality of life of these patients. Hydrotherapy is presented as a beneficial therapeutic option, based on the unique properties of water, for the treatment and rehabilitation of stroke patients, highlighting its potential to improve the mobility and quality of life of those affected.

show abstract

Neurological complications of coronary heart disease and their management

Cited by 2 publications

References 29 publications

Clinical value of long non‐coding RNA KCNQ1OT1 in estimating the stenosis, lipid level, inflammation status, and prognostication in coronary heart disease patients

Clinical value of long non‐coding RNA KCNQ1OT1 in estimating the stenosis, lipid level, inflammation status, and prognostication in coronary heart disease patients

Improvements in functionality and quality of life after aquatic therapy in stroke survivors

Contact Info

Product

Resources

About